重庆医学
重慶醫學
중경의학
CHONGQING MEDICAL JOURNAL
2015年
24期
3385-3388,3392
,共5页
奥曲肽%大黄属%急性病%胰腺炎%随机对照试验
奧麯肽%大黃屬%急性病%胰腺炎%隨機對照試驗
오곡태%대황속%급성병%이선염%수궤대조시험
Octreotide%rheum%acute disease%pancreatitis%randomized controlled trials
目的：系统评价大黄与奥曲肽联用治疗急性胰腺炎的有效性和安全性。方法计算机检索中国生物医学文献数据库(CBM)、维普(VIP)、中国知网(CNKI)、PubMed 和万方数据库,查找有关应用奥曲肽与大黄联用治疗急性胰腺炎的随机对照试验(RCT),并追索纳入文献的参考文献,检索时限：2008年1月至2014年12月。英文检索词为“Octreotide”,“rhubarb”,“ASP”,中文检索词为“大黄”、“奥曲肽”、“急性胰腺炎”。2位评价员按照 Corchrane 系统评价方法,预先制定纳入标准和排除标准,对检索的文献进行独立筛选、数据提取和文献评估,交叉核对相关数据,使用 RevMan 5.2软件分析。结果纳入10篇 RCT,共655例受试者(试验组336例,对照组319例)。Meta 分析结果显示：与单用奥曲肽相比,大黄联合奥曲肽可以提高显效率[RR=1.47,95%CI (1.21,1.78),P <0.01]和总有效率[RR=1.19,95%CI (1.09,1.29),P <0.01]；试验组与对照组在缩短腹痛时间、血淀粉酶恢复时间、排便恢复时间、患者住院时间、腹胀消失时间、呕吐消失时间、尿淀粉酶恢复时间、腹压痛消失时间方面,均差异有统计学意义(P <0.01)；可降低转手术率,但差异无统计学意义(P >0.05)；两组安全性方面未见严重不良反应报道。结论与单用奥曲肽相比,奥曲肽联合大黄治疗急性重症胰腺炎能提高奥曲肽的临床疗效,安全性较好。
目的：繫統評價大黃與奧麯肽聯用治療急性胰腺炎的有效性和安全性。方法計算機檢索中國生物醫學文獻數據庫(CBM)、維普(VIP)、中國知網(CNKI)、PubMed 和萬方數據庫,查找有關應用奧麯肽與大黃聯用治療急性胰腺炎的隨機對照試驗(RCT),併追索納入文獻的參攷文獻,檢索時限：2008年1月至2014年12月。英文檢索詞為“Octreotide”,“rhubarb”,“ASP”,中文檢索詞為“大黃”、“奧麯肽”、“急性胰腺炎”。2位評價員按照 Corchrane 繫統評價方法,預先製定納入標準和排除標準,對檢索的文獻進行獨立篩選、數據提取和文獻評估,交扠覈對相關數據,使用 RevMan 5.2軟件分析。結果納入10篇 RCT,共655例受試者(試驗組336例,對照組319例)。Meta 分析結果顯示：與單用奧麯肽相比,大黃聯閤奧麯肽可以提高顯效率[RR=1.47,95%CI (1.21,1.78),P <0.01]和總有效率[RR=1.19,95%CI (1.09,1.29),P <0.01]；試驗組與對照組在縮短腹痛時間、血澱粉酶恢複時間、排便恢複時間、患者住院時間、腹脹消失時間、嘔吐消失時間、尿澱粉酶恢複時間、腹壓痛消失時間方麵,均差異有統計學意義(P <0.01)；可降低轉手術率,但差異無統計學意義(P >0.05)；兩組安全性方麵未見嚴重不良反應報道。結論與單用奧麯肽相比,奧麯肽聯閤大黃治療急性重癥胰腺炎能提高奧麯肽的臨床療效,安全性較好。
목적：계통평개대황여오곡태련용치료급성이선염적유효성화안전성。방법계산궤검색중국생물의학문헌수거고(CBM)、유보(VIP)、중국지망(CNKI)、PubMed 화만방수거고,사조유관응용오곡태여대황련용치료급성이선염적수궤대조시험(RCT),병추색납입문헌적삼고문헌,검색시한：2008년1월지2014년12월。영문검색사위“Octreotide”,“rhubarb”,“ASP”,중문검색사위“대황”、“오곡태”、“급성이선염”。2위평개원안조 Corchrane 계통평개방법,예선제정납입표준화배제표준,대검색적문헌진행독립사선、수거제취화문헌평고,교차핵대상관수거,사용 RevMan 5.2연건분석。결과납입10편 RCT,공655례수시자(시험조336례,대조조319례)。Meta 분석결과현시：여단용오곡태상비,대황연합오곡태가이제고현효솔[RR=1.47,95%CI (1.21,1.78),P <0.01]화총유효솔[RR=1.19,95%CI (1.09,1.29),P <0.01]；시험조여대조조재축단복통시간、혈정분매회복시간、배편회복시간、환자주원시간、복창소실시간、구토소실시간、뇨정분매회복시간、복압통소실시간방면,균차이유통계학의의(P <0.01)；가강저전수술솔,단차이무통계학의의(P >0.05)；량조안전성방면미견엄중불량반응보도。결론여단용오곡태상비,오곡태연합대황치료급성중증이선염능제고오곡태적림상료효,안전성교호。
Objective To evaluate the efficacy and safety of the treatment with Octreotide combined with rhubarb for acute severe pancreatitis(ASP).Methods Randomized controlled trials(RCTs)were searched from the following data-bases as CBM、VIP、CNKI、PubMed and WanFang ,all RCTs searched from January 2008 to December 2014.Search terms were "Octreotide","rhubarb","ASP".Two reviewers according to the Cochrane systematic review,pre-defined inclusion and exclusion criteria,then screening literatures,extraction data and assessing literature′quality independently,finally unifided datas by cross-checked,Meta-a-nalysis was performed by RevMan5.2 software.Results Ten RCTs involving 655 patients (treatment group:336 cases,control group:31 9 cases)were included.Meta-analysis results showed that compared with the use of Octreotide,Octreotide combined rhu-barb advanced the clinical cure rates[RR=1.47,95%CI (1.21,1.78),P <0.01 ]and the total clinical effective rates [RR = 1.1 9, 95%CI (1.09,1.29),P <0.01];Octreotide combined rhubarb shorted the remission time of abdominal pain,the remission time of vomit,the recovery time of serum amylase,the recovery time of urine amylase,hospitalization days,the first defecation time,the ab-dominal distension disappear time and the remission time of signs of abdominal tenderness,the differences all above showed statisti-cal significance(P <0.01).But reducing the proportion of surgery didn′t have statistic difference(P >0.05).No severe adverse e-vents or allergic reactions were reported.Conclusion Compared with the traditional Octreotide therapy alone,rhubarb combined with Octreotide therapy for ASP have a better curative effect.
